Zogenix (NASDAQ:ZGNX)‘s stock had its “buy” rating reaffirmed by equities researchers at Mizuho in a research report issued to clients and investors on Thursday. They presently have a $69.00 target price on the stock. Mizuho’s target price indicates a potential upside of 62.16% from the company’s current price.
The analysts wrote, “We continue to see Fintepla as highly differentiated from competitor products with the potential for higher pricing and market share. The most important catalyst is a potential FDA approval in DS in 2019. Beyond DS, we see potential for for which data is anticipated in 1Q20.””
ZGNX has been the topic of several other research reports. Zacks Investment Research cut shares of Zogenix from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. ValuEngine cut shares of Zogenix from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. B. Riley began coverage on shares of Zogenix in a research report on Friday, September 7th. They issued a “buy” rating and a $116.00 price target on the stock. Leerink Swann set a $93.00 price target on shares of Zogenix and gave the company a “buy” rating in a research report on Saturday, October 6th. Finally, Stifel Nicolaus began coverage on shares of Zogenix in a research report on Wednesday, August 15th. They issued a “buy” rating and a $69.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Zogenix presently has an average rating of “Buy” and an average price target of $70.00.
Shares of NASDAQ ZGNX opened at $42.55 on Thursday. Zogenix has a fifty-two week low of $33.42 and a fifty-two week high of $62.75.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($1.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.20). During the same quarter last year, the company earned ($1.68) EPS. As a group, analysts forecast that Zogenix will post -3.84 EPS for the current year.
In other Zogenix news, Director Erle T. Mast sold 1,468 shares of Zogenix stock in a transaction that occurred on Monday, November 26th. The shares were sold at an average price of $42.08, for a total transaction of $61,773.44. Following the transaction, the director now owns 3,027 shares of the company’s stock, valued at approximately $127,376.16. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gail M. Farfel sold 6,961 shares of Zogenix stock in a transaction that occurred on Thursday, October 4th. The stock was sold at an average price of $43.23, for a total transaction of $300,924.03. Following the transaction, the executive vice president now directly owns 14,104 shares in the company, valued at approximately $609,715.92. The disclosure for this sale can be found here. 5.00% of the stock is currently owned by company insiders.
Several institutional investors have recently bought and sold shares of the business. Vident Investment Advisory LLC lifted its position in shares of Zogenix by 10.1% during the 2nd quarter. Vident Investment Advisory LLC now owns 13,633 shares of the company’s stock worth $603,000 after buying an additional 1,256 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Zogenix by 4.0% during the 3rd quarter. Wells Fargo & Company MN now owns 35,403 shares of the company’s stock worth $1,755,000 after buying an additional 1,355 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Zogenix by 25.6% during the 3rd quarter. Legal & General Group Plc now owns 6,948 shares of the company’s stock worth $344,000 after buying an additional 1,418 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Zogenix by 7.6% during the 3rd quarter. AQR Capital Management LLC now owns 23,221 shares of the company’s stock worth $1,152,000 after buying an additional 1,645 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Zogenix during the 3rd quarter worth approximately $109,000.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Featured Article: Yield Curve
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.